Goldman Sachs Maintains Sell on CME Gr, Raises Price Target to $198
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Alexander Blostein maintains a Sell rating on CME Group (NASDAQ:CME) but raises the price target from $195 to $198.
October 03, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a Sell rating on CME Group but slightly increased the price target from $195 to $198, indicating a cautious outlook.
The maintenance of a Sell rating suggests a negative outlook on CME Group's stock performance. The slight increase in the price target to $198 indicates a marginally improved valuation but still reflects a bearish sentiment. This could lead to downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100